Clinical Trial Search

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment — 9.4; 21.2 Percentage of participants

Primary: Change in HbA1c (Glycosylated Haemoglobin) From Baseline — -1.32; -1.61; -0.55 percentage of glycosylated haemoglobin — p=<0.0001

Primary: Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Fluconazole — 51.6; 51.0 nanogram per milliliter (ng/mL)

Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants

Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD) — 11.1; 0; 0; 16.7 percentage of…

Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397

Primary: Body Weight Change — -0.23; -5.13; -4.98 kg

Primary: Percentage of Participants Who Discontinued Due to Adverse Event — 4.65; 4.96 Percentage of Participants — p=1

Primary: Time to First Rehospitalization — 168; 139 Days to first readmission — p==.029

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD) — -2.74; -4.83; -4.62 Migraine Headache Days per Month — p=<.001

Primary: Percentage of Participants With Major Adverse Events (MAEs) — 0; 0; 0; 0 percentage of participants — p=<0.0001

Primary: Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population) — 0.38; -0.44; -3.09 percentage of fat — p=0.034

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -2.28; -4.29; -4.18 Migraine Headache Days per Month — p=<.001

Primary: Determination of HLA Type — 15; 5; 5; 1 subjects